By Liam Cosgrove | Mises Wire | September 11, 2021
Our healthcare system is broken, a fact nobody would have disputed in precovid days. Regulatory capture is a reality, and the pharmaceutical industry is fraught with examples. Yet we trusted private-public partnerships to find an optimal solution to a global pandemic, assuming a crisis would bring out the best in historically corrupt institutions.
The National Institutes of Health has awarded one-year supplemental grants totaling $1.67 million to five institutions to explore potential links between COVID-19 vaccination and menstrual changes. Some women have reported experiencing irregular or missing menstrual periods, bleeding that is heavier than usual, and other menstrual changes after receiving COVID-19 vaccines. The new awards support research to determine whether such changes may be linked to COVID-19 vaccination itself and how long the changes last. Researchers also will seek to clarify the mechanisms underlying potential vaccine-related menstrual changes.
“I see no need to rush the FDA approval process for any of the three COVID-19 vaccines. Expediting the process appears to only serve the political purpose of imposing and enforcing vaccine mandates,” Mr. Johnson wrote in the letter, a copy of which was obtained by The Washington Times.
…
U.S. Surgeon General Vivek Murthy told “Fox News Sunday” that moving the Pfizer vaccine from “emergency” to “full approval” would make mandates more appealing.
…
Former FDA Commissioner Scott Gottlieb, who is on the Pfizer board of directors, also said the full approval will prompt more vaccine mandates.
Just hours before the Pfizer vaccine news became public, Gottlieb appeared on CNBC’s Squawk Box to explain that any vaccine will need to be administered on an annual basis.
A national vaccine court has paid out billions to families who could prove their kids were injured by vaccines. But there’s only a skeletal program for the rare victims of covid vaccination, raising concerns as the pressure for mandated shots grows.
Pfizer announced its global phase 3 trial on a third dose in mid-July. That trial’s completion date is in 2022. Phase 3 results generally are required before regulatory approval.
“We are confident in this vaccine and the third dose, but you have to remember the vaccine efficacy study is still going on, so we need all the evidence to back up that,” Jerica Pitts, Pfizer’s director of global media relations, said Monday. The financial stakes are enormous: Pfizer announced in July that it expects $33.5 billion in covid-19 vaccine revenue this year.
…
The White House has added to the mixed messaging: Spokesperson Jen Psaki confirmed that the U.S. will buy an additional 200 million doses of the Pfizer-BioNTech vaccine for inoculating children under 12 and for possible boosters.
One of the world’s biggest vaccine proponents and strident defender of intellectual property rights is funding, directly and indirectly, large trials into cheap, off-patent, off-label COVID-19 treatments, including ivermectin.
You must be logged in to post a comment.